PDF herunterladen
Semin Respir Crit Care Med 2016; 37(06): 905-912
DOI: 10.1055/s-0036-1592133
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Principles of Antibiotic Management of Community-Acquired Pneumonia

Michael T. Bender
1   NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York
,
Michael S. Niederman
2   Department of Medicine, Weill Cornell Medical College, New York, New York
3   Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Dezember 2016 (online)

    Lizenzen und Reprints

Abstract

Community-acquired pneumonia (CAP) encompasses a broad spectrum of disease severity and may require outpatient, inpatient, or intensive care management. Successful treatment hinges on expedient delivery of appropriate antibiotic therapy tailored to both the likely offending pathogens and the severity of disease. This review summarizes key principles in starting treatment and provides recommended empiric therapy regimens for each site of care. In addition, we discuss the antimicrobial and anti-inflammatory role macrolides play in CAP, as well as specific information for managing individual CAP pathogens such as community-acquired methicillin-resistant Staphylococcus aureus and drug-resistant Streptococcus pneumoniae. We also examine several novel antibiotics being developed for CAP and review the evidence guiding duration of therapy and current best practices for the transition of hospitalized patients from intravenous antibiotics to oral therapy.

Keywords

pneumonia - initiation of antibiotics - duration of antibiotics - macrolides - clinical outcomes
 

  • References

  • 1 Mandell LA, Wunderink RG, Anzueto A , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    CrossrefPubMedGoogle Scholar
  • 2 Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 2016; 315 (6) 593-602
    CrossrefPubMedGoogle Scholar
  • 3 Lee JS, Nsa W, Hausmann LR , et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med 2014; 174 (11) 1806-1814
    CrossrefPubMedGoogle Scholar
  • 4 Meehan TP, Fine MJ, Krumholz HM , et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278 (23) 2080-2084
    CrossrefPubMedGoogle Scholar
  • 5 Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001; 161 (17) 2099-2104
    CrossrefPubMedGoogle Scholar
  • 6 Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164 (6) 637-644
    CrossrefPubMedGoogle Scholar
  • 7 Arnold FW, Summersgill JT, Lajoie AS , et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175 (10) 1086-1093
    CrossrefPubMedGoogle Scholar
  • 8 Simonetti A, Viasus D, Garcia-Vidal C , et al. Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. Clin Microbiol Infect 2012; 18 (11) 1149-1155
    CrossrefPubMedGoogle Scholar
  • 9 Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130 (1) 11-15
    CrossrefPubMedGoogle Scholar
  • 10 Lee JS, Primack BA, Mor MK , et al. Processes of care and outcomes for community-acquired pneumonia. Am J Med 2011; 124 (12) 1175.e9-1175.e17
    CrossrefPubMedGoogle Scholar
  • 11 Kumar A, Roberts D, Wood KE , et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34 (6) 1589-1596
    CrossrefPubMedGoogle Scholar
  • 12 Levy MM, Dellinger RP, Townsend SR , et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36 (2) 222-231
    CrossrefPubMedGoogle Scholar
  • 13 Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007; 131 (6) 1865-1869
    CrossrefPubMedGoogle Scholar
  • 14 Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008; 168 (4) 351-356
    CrossrefPubMedGoogle Scholar
  • 15 Polgreen PM, Chen YY, Cavanaugh JE , et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28 (2) 212-214
    CrossrefPubMedGoogle Scholar
  • 16 Daniel P, Rodrigo C, Mckeever TM, Woodhead M, Welham S, Lim WS ; British Thoracic Society. Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysis. Thorax 2016; 71 (6) 568-570
    CrossrefPubMedGoogle Scholar
  • 17 Read RC. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999; 39 (3) 171-178
    CrossrefPubMedGoogle Scholar
  • 18 Jain S, Self WH, Wunderink RG , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (5) 415-427
    CrossrefPubMedGoogle Scholar
  • 19 Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99 (1) 60-65
    CrossrefPubMedGoogle Scholar
  • 20 Cillóniz C, Ewig S, Polverino E , et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66 (4) 340-346
    CrossrefPubMedGoogle Scholar
  • 21 Ramsdell J, Narsavage GL, Fink JB ; American College of Chest Physicians' Home Care Network Working Group. Management of community-acquired pneumonia in the home: an American College of Chest Physicians clinical position statement. Chest 2005; 127 (5) 1752-1763
    CrossrefPubMedGoogle Scholar
  • 22 Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A ; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40 (9) 1288-1297
    CrossrefPubMedGoogle Scholar
  • 23 Campbell Jr GD, Silberman R. Drug-resistant Streptococcus pneumoniae . Clin Infect Dis 1998; 26 (5) 1188-1195
    CrossrefPubMedGoogle Scholar
  • 24 Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133 (3) 610-617
    CrossrefPubMedGoogle Scholar
  • 25 Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L , et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40 (6) 800-806
    CrossrefPubMedGoogle Scholar
  • 26 Sabrià M, Pedro-Botet ML, Gómez J , et al; Legionnaires Disease Therapy Group. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128 (3) 1401-1405
    CrossrefPubMedGoogle Scholar
  • 27 Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011; 81 (1) 67-74
    CrossrefPubMedGoogle Scholar
  • 28 Postma DF, van Werkhoven CH, van Elden LJ , et al; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372 (14) 1312-1323
    CrossrefPubMedGoogle Scholar
  • 29 Garin N, Genné D, Carballo S , et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174 (12) 1894-1901
    CrossrefPubMedGoogle Scholar
  • 30 Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014; 42 (2) 420-432
    CrossrefPubMedGoogle Scholar
  • 31 Baddour LM, Yu VL, Klugman KP , et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170 (4) 440-444
    CrossrefPubMedGoogle Scholar
  • 32 Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33 (1) 153-159
    CrossrefPubMedGoogle Scholar
  • 33 Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123 (5) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 34 Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011; 63 (3) 187-199
    CrossrefPubMedGoogle Scholar
  • 35 Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001; 43 (5) (Suppl. 01) 1-45
    CrossrefPubMedGoogle Scholar
  • 36 Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus . Clin Infect Dis 2008; 46 (Suppl. 05) S378-S385
    CrossrefPubMedGoogle Scholar
  • 37 Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?. Infect Dis Clin North Am 2013; 27 (1) 177-188
    CrossrefPubMedGoogle Scholar
  • 38 Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198 (8) 1166-1170
    CrossrefPubMedGoogle Scholar
  • 39 Diep BA, Afasizheva A, Le HN , et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 2013; 208 (1) 75-82
    CrossrefPubMedGoogle Scholar
  • 40 Sicot N, Khanafer N, Meyssonnier V , et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia—results of a prospective observational study. Clin Microbiol Infect 2013; 19 (3) E142-E148
    CrossrefPubMedGoogle Scholar
  • 41 Bernardo K, Pakulat N, Fleer S , et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48 (2) 546-555
    CrossrefPubMedGoogle Scholar
  • 42 Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus . J Infect Dis 2007; 195 (2) 202-211
    CrossrefPubMedGoogle Scholar
  • 43 Faris J, Mynatt RP, Hall Snyder AD, Rybak MJ. Treatment of methicillin-resistant Staphylococcal aureus (MRSA) pneumonia with ceftaroline fosamil in a patient with inhalational thermal injury. Infect Dis Ther 2015; 4 (4) 519-528
    CrossrefPubMedGoogle Scholar
  • 44 Clavo-Sánchez AJ, Girón-González JA, López-Prieto D , et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24 (6) 1052-1059
    CrossrefPubMedGoogle Scholar
  • 45 Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36 (9) 1132-1138
    CrossrefPubMedGoogle Scholar
  • 46 Moroney JF, Fiore AE, Harrison LH , et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33 (6) 797-805
    CrossrefPubMedGoogle Scholar
  • 47 Yu VL, Chiou CC, Feldman C , et al; International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37 (2) 230-237
    CrossrefPubMedGoogle Scholar
  • 48 Falagas ME, Siempos II, Bliziotis IA, Panos GZ. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 2006; 81 (12) 1567-1574
    CrossrefPubMedGoogle Scholar
  • 49 File Jr TM, Segreti J, Dunbar L , et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41 (9) 1965-1972
    PubMedGoogle Scholar
  • 50 Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30 (4) 397-404
    CrossrefPubMedGoogle Scholar
  • 51 Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH ; Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42 (1) 73-81
    CrossrefPubMedGoogle Scholar
  • 52 Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179 (12) 1269-1277
    CrossrefPubMedGoogle Scholar
  • 53 Ruhe J, Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?. Infect Dis Clin North Am 2013; 27 (1) 115-132
    CrossrefPubMedGoogle Scholar
  • 54 Rodríguez-Avial I, Ramos B, Ríos E, Cercenado E, Ordobás M, Sanz JC ; Madrid Streptococcus pneumoniae Microbiological Group. Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009. Antimicrob Agents Chemother 2011; 55 (5) 2469-2471
    CrossrefPubMedGoogle Scholar
  • 55 Spellberg B, Bartlett J, Wunderink R, Gilbert DN. Novel approaches are needed to develop tomorrow's antibacterial therapies. Am J Respir Crit Care Med 2015; 191 (2) 135-140
    CrossrefPubMedGoogle Scholar
  • 56 Barrera CM, Mykietiuk A, Metev H , et al; SOLITAIRE-ORAL Pneumonia Team. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis 2016; 16 (4) 421-430
    CrossrefPubMedGoogle Scholar
  • 57 van Rensburg DJ, Perng RP, Mitha IH , et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 2010; 54 (10) 4098-4106
    CrossrefPubMedGoogle Scholar
  • 58 Choi D, Kim YS, Kim MJ , et al. A phase 2, multidose, double-blind, randomized, multicenter, comparative study of zabofloxacin vs moxifloxacin in the treatment of mild to moderate community-acquired pneumonia [abstract]. Presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9–12, 2012, San Francisco, California, L1–L294
    PubMedGoogle Scholar
  • 59 Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 2013; 4 (2) 185-191
    CrossrefPubMedGoogle Scholar
  • 60 Boucher HW, Talbot GH, Benjamin Jr DK , et al; Infectious Diseases Society of America. 10 x '20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56 (12) 1685-1694
    PubMedGoogle Scholar
  • 61 Woodhead M, Blasi F, Ewig S , et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 2011; 17 (Suppl. 06) E1-E59
    PubMedGoogle Scholar
  • 62 Lim WS, Baudouin SV, George RC , et al; Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 03) iii1-iii55
    CrossrefPubMedGoogle Scholar
  • 63 Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120 (9) 783-790
    CrossrefPubMedGoogle Scholar
  • 64 Liu C, Bayer A, Cosgrove SE , et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52 (3) e18-e55
    CrossrefPubMedGoogle Scholar
  • 65 Schuetz P, Müller B, Christ-Crain M , et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health 2013; 8 (4) 1297-1371
    CrossrefPubMedGoogle Scholar
  • 66 Oosterheert JJ, Bonten MJ, Schneider MM , et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333 (7580) 1193-1195
    CrossrefPubMedGoogle Scholar
  • 67 Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155 (12) 1273-1276
    CrossrefPubMedGoogle Scholar
  • 68 Ramirez JA, Vargas S, Ritter GW , et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159 (20) 2449-2454
    CrossrefPubMedGoogle Scholar
  • 69 Lodise TP, Anzueto AR, Weber DJ , et al. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrob Agents Chemother 2015; 59 (2) 1119-1126
    CrossrefPubMedGoogle Scholar
  • 70 Carratalà J, Garcia-Vidal C, Ortega L , et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012; 172 (12) 922-928
    PubMedGoogle Scholar
  • 71 Murray C, Shaw A, Lloyd M , et al. A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother 2014; 69 (2) 515-518
    CrossrefPubMedGoogle Scholar
  • 72 Fishbane S, Niederman MS, Daly C , et al. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med 2007; 167 (15) 1664-1669
    CrossrefPubMedGoogle Scholar